Arsenal Medical, a leader in developing biomaterials-based devices, announced the appointment of Ray Baker, M.D., to the Arsenal Medical Board of Directors, effective immediately. 

“We are thrilled to welcome Dr. Baker to our Board of Directors,” said Upma Sharma, Ph.D., President and CEO of Arsenal Medical. “His appointment comes at a pivotal time for Arsenal as we advance our NeoCast™ and ResQFoam™ products in the clinic and accelerate the development of novel biomaterials in new therapeutic areas in neurointervention and beyond. Dr. Baker’s deep clinical expertise, and proven track record of leadership and growth as a healthcare executive will further strengthen our organization as we create and deploy biomaterials where they are needed most.”

Dr. Baker currently serves as Chief Medical Officer of Neuromodulation at Boston Scientific. Prior to this role, he was the Chief Medical Officer at Relievant Medical Systems, where he was instrumental in the commercial introduction of the Intracept procedure, a minimally invasive treatment for chronic low back pain caused by degenerative disc disease. 

Before joining Relievant, Dr. Baker held leadership positions at Evergreen Health in Kirkland, Wash., serving as Vice President and Executive Medical Director. His expertise includes both academic and private practice settings, having previously served as a Clinical Professor and Director of Interventional Pain Services at the University of Washington. Additionally, he Chaired the Multi-Society Pain Workgroup for the Centers for Medicare and Medicaid Services (CMS) and is the past President of both the North American Spine Society and the International Pain & Spine Intervention Society (formerly the Spine Intervention Society). 

Dr. Baker began his career as an anesthesiologist specializing in interventional pain medicine and non-surgical spine care. He holds a bachelor’s degree from the University of California, Berkeley, and a medical degree from the University of California, Irvine. In recognition of his outstanding contributions to interventional pain management, he was honored with the prestigious Charles N. Aprill Lifetime Achievement Award from the International Pain & Spine Intervention Society in 2023. 

"I am looking forward to joining Arsenal's board during this exciting time for the company,” said Dr. Baker. “Developing next-generation biomaterials for minimally invasive therapies has the potential to significantly enhance the physician experience and improve patient outcomes. I look forward to supporting Arsenal’s vision of creating innovative biomaterials to transform medicine.”